NOTCH2 Monoclonal Antibody (16F11), PE, eBioscience™, Invitrogen™

Description

Description: This 16F11 monoclonal antibody reacts with the extracellular domain of human and mouse Notch2, one of four members of the Notch family of receptors. Notch receptors are 300-kDa single-pass transmembrane proteins. While the extracellular domain contains numerous epidermal growth factor-like repeats for ligand binding, the intracellular domain is involved in cell signaling. Upon binding its membrane-bound ligand (either Delta or Jagged), the Notch receptor undergoes proteolytic cleavage, first by ADAM-family metalloproteases and then by gamma-secretase. The second cleavage event releases the Notch intracellular domain (NICD), which subsequently translocates into the nucleus, heterodimerizes with the DNA-binding protein RBP-J, recruits co-activator molecules, and ultimately activates transcription. Notch2 is expressed on thymocytes (i.e., DN1 and DN2 subsets), activated peripheral T cells, and bone marrow. Moreover, expression of Notch2 has been reported to be altered in various cancers and lymphomas. In addition to its role in stem cell hematopoiesis, Notch2 plays a pivotal role in marginal zone B cell development. Notch2 also interacts with phosphorylated CREB1 to induce granzyme B transcription in cytotoxic T cells. Applications Reported: This 16F11 antibody has been reported for use in flow cytometric analysis. Applications Tested: This 16F11 antibody has been tested by flow cytometric analysis of 24-hour anti-CD3-stimulated mouse splenocytes.

Neurogenic locus notch homolog protein 2 (NOTCH2) is a highly conserved Notch signaling pathway protein. NOTCH2 is a type 1 transmembrane protein with an extracellular domain consisting of multiple epidermal growth factor-like (EGF) repeats, and an intracellular domain consisting of multiple, different domain types. NOTCH2 functions as a receptor for membrane-bound ligands Jagged1, Jagged2 and Delta1 to regulate cell-fate determination. Defects in NOTCH2 are the cause of Alagille syndrome type 2 (ALGS2). Alagille syndrome is an autosomal dominant multisystem disorder defined clinically by hepatic bile duct paucity and cholestasis in association with cardiac, skeletal, and ophthalmologic manifestations. There are characteristic facial features and less frequent clinical involvement of the renal and vascular systems.